Kidney Cancer | Tumor

CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.

Integrative Care May Be Beneficial During Treatment for Kidney Cancer

November 7th 2022

As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga, a patient advocate, about integrative care for kidney cancer.

Speaking Out About Side Effects From Kidney Cancer Treatment

November 7th 2022

As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga, a patient advocate, about the side effects associated with kidney cancer treatment.

Patients Should Stay Educated on the Growing Treatment Options for Kidney Cancer

November 7th 2022

As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga about the importance of patients being their own advocate when communicating with their physician.

Setting Expectations in a Patient-Physician Relationship Following a Kidney Cancer Diagnosis

November 7th 2022

As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga about the importance of patients being their own advocate when communicating with their physician.

My 6 Rules for Navigating Cancer and Medical Misdiagnoses

October 31st 2022

I was misdiagnosed twice before receiving my kidney cancer diagnosis, and along the way, I learned the importance of expert doctors and clinical trials.

The Past 20 Years Have Been Revolutionary for Kidney Cancer

October 19th 2022

Once seen as a malignancy resistant to typical treatments such as chemotherapy, metastatic kidney cancer has come a long way in the past 20 years.

The Last 20 Years of Advancements Were 'Revolutionary' for Metastatic Kidney Cancer Treatment

October 12th 2022

Twenty years of FDA approvals for the treatment of metastatic kidney cancer have allowed patients to live longer.

FDA Approves Avastin Biosimilar to Treat Six Diseases Including Certain Colon, Lung, Kidney Cancers

September 28th 2022

The FDA’s approval of Vegzelma was based on data that demonstrated the biosimilar elicited comparable safety and efficacy to Avastin in several studies.

Telaglenastat-Cabometyx Combination May Not Improve Survival in Pretreated Kidney Cancer Compared With Cabometyx Alone

September 20th 2022

Although patients treated with the combination did not have significant improvements in survival, telaglenastat and Cabometyx did not increase the rate of side effects in patients.

Adding Cabometyx to Immunotherapy Combination Improves Outcomes for Advanced Kidney Cancer

September 12th 2022

The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer.

Expert Breaks Down What Patients With Kidney Cancer Need to Know About Surgery as a Treatment Option

August 30th 2022

An expert explains the different types of kidney cancer surgeries, and what patients can expect to experience after the procedure.

Immunotherapy Duo Fails to Improve Disease-Free Survival in Patients With Kidney Cancer Following Surgery

July 29th 2022

Findings from the CheckMate-914 trial showed that Opdivo plus Yervoy did not meet the study’s main goal of disease-free survival for patients with localized renal cell carcinoma, a type of kidney cancer.

Novel Drug to Be Investigated With Keytruda in Advanced Solid Cancers

July 27th 2022

A new treatment group within the PYNNACLE clinical trial is set to evaluate a novel drug plus Keytruda in patients with p53 Y220C-mutant locally advanced or metastatic solid tumors.

Popular Minecraft Creator and YouTuber, Technoblade, Dies of Rare Cancer, ‘General Hospital’ Star Discusses Life After Cancer and More

July 1st 2022

From “General Hospital” star Cameron Mathison discussing his cancer experience to Dame Deborah James and Hells Angels founder Sonny Barger dying of the disease, here’s what happened in the cancer space this week.

Future Perspectives in Renal Cell Carcinoma (RCC)

June 29th 2022

Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.

Zenocutuzumab ‘Offers Potential New Standard of Care’ for NRG1-Positive Solid Cancers

June 9th 2022

With no approved therapies for NRG-1 cancers, zenocutuzumab offers a promising treatment option for this patient population.

Lenvima Plus Keytruda May Become Next Standard-of-Care Treatment Option for Advanced Kidney Cancer

June 5th 2022

Treatment with Lenvima plus Keytruda resulted in a 50% decrease in risk of disease progression or death compared with Sutent in patients with advanced kidney cancer.

Clinical Trial to Assess Experimental Drug as Single-Agent, and Combined With Keytruda Across Several Solid Tumors Launches

May 25th 2022

The aim of the early-stage trial is to identify the safety of the experimental drug as either a single-agent therapy as well as in combination with Keytruda in adults with multiple solid tumors.

Cancer Trial Hopes to Find New Patient Populations That Will Respond to Already-Approved Drugs

May 19th 2022

The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.

Kidney Cancer Nurse Is an Icon in Her Field

May 8th 2022

Laura Wood, M.S.N., RN, OCN, has "skill, dedication, boundless compassion and drive to improve the lives of those affected by kidney cancer."

Unmet Needs and Future Perspectives in the Treatment of RCC

May 5th 2022

Bryan Lewis, president of KidneyCAN, and Chung-Han Lee, MD, describe unmet needs and future perspectives in the treatment of renal cell carcinoma.

The Importance of Patients Advocating for Themselves During Their RCC Journey

May 5th 2022

Meryl Uranga describes her path with metastatic clear cell renal cell carcinoma after first treatment, and how it has affected her outlook on her life and future.

Quality-of-Life with Systemic Therapies in Metastatic Clear Cell RCC

May 5th 2022

A look at how to consider quality-of-life clinical trial and patient-reported data when treating clear cell renal cell carcinoma with combination therapies.

Nurse Helps Patients Through Education and Cancer Care Protocols

May 4th 2022

Christine Amoroso, B.S.N., RN, OCN, figured out the best way to deliver direct-to-kidney treatment for her patients.

Patient Experience with Systemic Therapy-Related Toxicities in Metastatic RCC

May 2nd 2022

Meryl Uranga describes her personal experience with managing the side effects of treatment for clear cell renal cell carcinoma.

Adverse Events Associated with IO-TKI Therapies in Metastatic Clear Cell RCC

May 2nd 2022

An overview of side effects commonly seen with lenvatinib plus pembrolizumab for the treatment of clear cell renal cell carcinoma.

Educated Patient® Kidney Cancer Summit Combination Therapy Panel: April 9, 2022

May 1st 2022

Watch Dr. Thomas Hutson, Dr. Saby George, Dr. Jeff Yorio and Louise Gunter answer questions about combination therapy, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit IO/TKI-Related Side Effects Presentation: April 9, 2022

April 30th 2022

Watch Louise Gunter, from Texas Oncology, discuss IO/TKI-related side effects, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit IO/TKI Therapies Presentation: April 9, 2022

April 29th 2022

Watch Dr. Jeff Yorio, from Texas Oncology, discuss treatment with the combination of immunotherapy and tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit IO/IO Therapies Presentation: April 9, 2022

April 28th 2022

Watch Dr. Saby George, from Roswell Park Comprehensive Cancer Center, discuss treatment with the combination of immunotherapies, during the CURE Educated Patient Kidney Cancer Summit.

NEXT PAGE
PREVIOUS PAGE